149 related articles for article (PubMed ID: 21289145)
1. Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations.
Young TP; Cloherty G; Fransen S; Napolitano L; Swanson P; Herman C; Parkin NT; Hackett J
J Clin Microbiol; 2011 Apr; 49(4):1631-4. PubMed ID: 21289145
[TBL] [Abstract][Full Text] [Related]
2. Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir.
Young TP; Napolitano LA; Paquet AC; Parkin NT; Fransen S; Trinh R; Haddad M; Hackett J; Cloherty GA
J Virol Methods; 2013 Nov; 193(2):693-6. PubMed ID: 23892128
[TBL] [Abstract][Full Text] [Related]
3. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece.
Katsoulidou A; Rokka C; Issaris C; Haida C; Tzannis K; Sypsa V; Detsika M; Paraskevis D; Hatzakis A
Virol J; 2011 Jan; 8():10. PubMed ID: 21219667
[TBL] [Abstract][Full Text] [Related]
5. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
6. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
Armenia D; Vandenbroucke I; Fabeni L; Van Marck H; Cento V; D'Arrigo R; Van Wesenbeeck L; Scopelliti F; Micheli V; Bruzzone B; Lo Caputo S; Aerssens J; Rizzardini G; Tozzi V; Narciso P; Antinori A; Stuyver L; Perno CF; Ceccherini-Silberstein F
J Infect Dis; 2012 Feb; 205(4):557-67. PubMed ID: 22238474
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
[No Abstract] [Full Text] [Related]
8. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2 test using the TaqMan 48 analyzer and the Abbott RealTime HIV-1 assay.
van Rensburg EJ; Tait K; Watt A; Schall R
J Clin Microbiol; 2011 Jan; 49(1):377-9. PubMed ID: 20980564
[TBL] [Abstract][Full Text] [Related]
11. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
12. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
[TBL] [Abstract][Full Text] [Related]
13. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
14. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
Reuman EC; Bachmann MH; Varghese V; Fessel WJ; Shafer RW
Antimicrob Agents Chemother; 2010 Feb; 54(2):934-6. PubMed ID: 19917747
[TBL] [Abstract][Full Text] [Related]
15. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 integrase inhibitor resistance and its clinical implications.
Blanco JL; Varghese V; Rhee SY; Gatell JM; Shafer RW
J Infect Dis; 2011 May; 203(9):1204-14. PubMed ID: 21459813
[TBL] [Abstract][Full Text] [Related]
17. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.
Fransen S; Gupta S; Frantzell A; Petropoulos CJ; Huang W
J Virol; 2012 Jul; 86(13):7249-55. PubMed ID: 22553340
[TBL] [Abstract][Full Text] [Related]
18. No residual activity of raltegravir after development of 148 complex mutations in vivo.
Khanlou H; Sayana S; Acosta E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
[No Abstract] [Full Text] [Related]
19. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
Marsden MD; Avancena P; Kitchen CM; Hubbard T; Zack JA
Antimicrob Agents Chemother; 2011 Aug; 55(8):3696-702. PubMed ID: 21628534
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
